YAMASA CORPORATION Biochemicals Division

YAMASA CORPORATION Biochemicals Division

CONTACT YAMASA CORPORATION SITE

YAMASA CORPORATION Biochemicals Division

CONTACT YAMASA CORPORATION SITE
Leading manufacturing company
of nucleic acid related compounds
Summer 2022
Completion of new drug substance manufacturing building!

Strengthen production system of amidite monomer for mass synthesis of GMP-compatible oligonucleic acid.

More Info
Frequently asked questions
organized by use and purpose.

We are here to fulfill the aspirations of our clients.
Please feel free to inquire.

More

also available in

French Spanish

  • 2022.10.26 We invested to Liid Pharmaceuticals, Inc. who is developing oligonucleotide therapeutics especially in the field of circulatory disease. Please refer the web page of Liid Pharmaceuticals for details.
  • 2022.10.18 There have been fraudulent acts of pretending to be our company and offering transactions using an email address "info@yamasa-biochems.com" which does not belong to our company. Also, the name "Matsuyama Takao" has been used in this act, but she is not an employee of our company. If you receive an email from “info@yamasa-biochems.com”, please be careful.
    Note: The website URL of Biochemicals Division of Yamasa Corporation is "https://www.yamasa-biochem.com/" and the email domain of the fraudulent email is "yamasa-biochems.com".
  • 2022.9.14 Yamasa will exhibit at TIDES Europe 2022 (11/16-11/18). We will promote the new API plant for oligonucleotides and modified nucleotides used for mRNA synthesis.
  • 2022.9.14 Yamasa will exhibit at CPhI Frankfurt 2022 (11/1-11/3). We will promote the new API plant for oligonucleotides and modified nucleotides used for mRNA synthesis in addition to small molecular APIs.
  • 2022.9.14 Yamasa will exhibit at BioJapan 2022 (10/12-10/14). We will promote the new API plant for oligonucleotides and modified nucleotides used for mRNA synthesis.
  • 2022.8.24 The article of our new API factory for oligonucleotides is posted to Yakujinippo.
  • 2022.6.14 The article of Yamasa's pseudouridine is posted in the whitepaper published by Ministry of Education, Culture, Sports, Science and Technology of Japan.
  • 2022.5.25 The new page introducing the oligonucleotide API plant is launched.
  • 2022.4.22 Yamasa will exhibit at the 7th Annual Meeting of the Nucleic Acids Therapeutics Society of Japan (7/31-8/3). We will promote the new API plant for oligonucleotides and modified nucleotides used for mRNA synthesis.
  • 2022.4.22 Yamasa will exhibit at in-PHARMA JAPAN 2022 (7/13-7/15). We will promote the new API plant for oligonucleotides and modified nucleotides used for mRNA synthesis.
  • 2022.4.1 Yamasa will exhibit at CPhI Japan 2022 (4/20-4/22).
  • 2022.2.22 The article of our modified nucleotides used for mRNA synthesis and the new API factory for oligonucleotides is posted to Japan Chemical Dairy.
  • 2021.10.13 Yamasa will exhibit at the 23rd INTERPHEX Week Tokyo (12/8-12/10). We will promote the materials used for mRNA synthesis and the new API plant.
  • 2021.10.10 The article of Yamasa’s Pseudouridine for mRNA synthesis is posted to NTV News 24.
  • 2021.9.22 The article of Yamasa’s Pseudouridine for mRNA synthesis is posted to NewsPicks..
  • 2021.6.21 As a general food application, we introduce "nucleotides" as new functional ingredients that help maintain health and improve quality of life. For more information, please contact us on the "Contact by e-mail" page.
  • 2021.6.21 Yamasa will exhibit at the 6th Annual Meeting of the Nucleic Acids Therapeutics Society of Japan(6/27-6/29). We will promote the materials used for mRNA synthesis.
  • 2021.6.21 The materials used for mRNA synthesis are added to Product List page.
  • 2021.3.8 The article of construction of our new API factory is posted to Japan Chemical Dairy. Yamasa will manufacture oligonucleotides under GMP control using this facility.
  • 2019.12.1 Yamasa launched new pages of monomers used in drug development of oligonucleotides and custom synthesis of oligonucleotides. Please see assist in drug development of oligonucleotides.
  • 2019.12.1 Yamasa will exhibit at CPhI Japan (booth 1H-50) March 16 - March 18, 2020.
  • 2019.12.1 Yamasa will exhibit at Asia Tides (booth 11) February 24 - February 26, 2020.
  • 2019.10.1 Yamasa will exhibit at CPhI worldwide (booth 40A43) November 5 - November 7, 2019.
  • 2019.8.23 Yamasa will exhibit at CPhI worldwide (booth 40A43) November 5 - November 7, 2019.
  • 2019.3.04 Yamasa will exhibit at in-PHARMA JAPAN (booth A6-50) July 3 - July 5, 2019.
  • 2019.3.04 Yamasa will exhibit at CPhI North America (booth 1032) April 30 - May 2, 2019.
  • 2019.3.04 Yamasa will exhibit at CPhI Japan (booth 2B-07) March 18 - March 20, 2019
  • 2018.9.25 Yamasa will exhibit at CPhI worldwide (booth 5A4) October 9 - October 11, 2018.
  • 2018.4.2 Yamasa undertakes a joint research project with Gifu University on novel oligonucleotide derivatives containing 4’-aminoalkyl-nucleoside discovered by professor Ueno. Yamasa works on process development of nucleoside amidites used for these oligomers syntheses.
  • 2018.4.2 Yamasa will exhibit at CPhI Japan (booth L-09) April 18 - April 20, 2018.
  • 2018.4.2 Yamasa will exhibit at CPhI North America (booth 664) April 24 - April 26, 2018.
  • 2018.4.2 New WEB site is opened.
see more

Inquiry by e-mail

Contact by e-mail

Inquiry by telephone

(Reception hours 9:00~17:30)